Stocks
Kymera Therapeutics, Inc.KYMR
NASDAQHealthcareBiotechnology$104.78
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing targeted protein degradation therapies, primarily for oncology and immunology indications. Its lead programs focus on IRAK4 and STAT3 degraders, with early-stage data that investors monitor closely for proof-of-concept in inflammatory diseases and solid tumors.
52W Range: $55.26-$130.05
Congressional Interest in Kymera Therapeutics, Inc. (KYMR)
No congressional trades have been disclosed for Kymera Therapeutics, Inc. (KYMR) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading KYMR?
No congressional trades found for this stock.